Maine is currently home to 208 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Bangor, Portland, Scarborough and Auburn. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491
Recruiting
The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.
Gender:
MALE
Ages:
Between 18 years and 130 years
Trial Updated:
08/06/2025
Locations: Research Site, Scarborough, Maine
Conditions: Metastatic Castration-Sensitive Prostate Cancer
Register for Updates
A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease
NCT06822517
Recruiting
This trial is a randomized, double-blind, placebo-controlled Phase 1b study evaluating the safety/tolerability, PK, and pharmacodynamics of VENT 02, administered orally at 1 dose level twice daily (BID) over 28 days in patients with mild to moderate Parkinson's disease. The study includes a screening period, a 28-day double-blind treatment period, and a 7-day follow-up period after last dose. Approximately 30 patients will be randomized into 1 of the 2 treatment arms.
Gender:
ALL
Ages:
Between 45 years and 90 years
Trial Updated:
08/06/2025
Locations: Investigative Site, Scarborough, Maine
Conditions: Parkinson Disease
Register for Updates
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
NCT06551324
Recruiting
Pfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician's choice of either second-line androgen receptor (AR) directed therapy with enzalutamide or docetaxel (chemotherapy) for treating metastatic castration-resistant prostate cancer (mCRPC) after progression on prior abiraterone acetate treatment. The primary objective of this clinical trial is... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: New England Cancer Specialists, Topsham, Maine
Conditions: Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Register for Updates
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
NCT02693535
Recruiting
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers). \*\*\*\*\*\*\*\*\*\*\*\*\*... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
08/05/2025
Locations: Harold Alfond Center for Cancer Care, Augusta, Maine
Conditions: Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
Register for Updates
Posterior Wall Substrate Modification Using Irreversible Electroporation for Paroxysmal Atrial Fibrillation
NCT06364215
Recruiting
The purpose of this study is to compare the efficacy and safety between pulmonary vein isolation (PVI) alone versus PVI with left atrial (LA) posterior wall isolation (PWI) using pulsed-field ablation (PFA) in the treatment of patients with paroxysmal atrial fibrillation (PAF).
Gender:
ALL
Ages:
Between 21 years and 90 years
Trial Updated:
08/05/2025
Locations: Maine Medical Center, Portland, Maine
Conditions: Atrial Fibrillation Paroxysmal
Register for Updates
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
NCT05918861
Recruiting
This is a placebo-controlled, randomized, double-blind, parallel group, phase 3 multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will provide informed consent before any study-specific procedures are performed. A separate informed consent will be allowed for an initial pre-screening genetic testing. Subjects meeting the AA genotype will then consent to the full study and confirmatory genetic testing as required. Subject enrollment may... Read More
Gender:
ALL
Ages:
45 years and above
Trial Updated:
08/05/2025
Locations: Research Site, Bangor, Maine
Conditions: Acute Coronary Syndrome
Register for Updates
Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration
NCT04567303
Recruiting
This is a first in-human study to investigate the safety, tolerability and efficacy of zifibancimig administered through intravitreal (IVT) injections and via the Port Delivery (PD) implant in participants with neovascular age-related macular degeneration (nAMD).
Gender:
ALL
Ages:
50 years and above
Trial Updated:
08/04/2025
Locations: Maine Eye Center, Portland, Maine
Conditions: Macular Degeneration
Register for Updates
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
NCT06191744
Recruiting
Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will assess how safe and effective epcoritamab is in combination with lenalidomide and rituximab (R2) in treating adult participants with previously untreated FL. Adverse events and change in disease condition will be assessed. Epcoritamab is an investigat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: New England Cancer Specialists - Westbrook /ID# 260672, Westbrook, Maine
Conditions: Follicular Lymphoma (FL)
Register for Updates
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
NCT04468061
Recruiting
This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The names of the study interventions involved in this study are: * Sacituzumab govitecan (Trodelvy™;IMMU-132) * Pembrolizumab (Keytruda®; MK-3475)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: Eastern Maine Medical Center, Brewer, Maine
Conditions: Breast Cancer, Triple Negative Breast Cancer, PD-L1 Negative
Register for Updates
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
NCT06418204
Recruiting
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies with chemotherapy and/or (immune checkpoint inhibitors) ICIs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/02/2025
Locations: Harold Alfond Center for Cancer Care, Augusta, Maine
Conditions: Breast Carcinoma, Colorectal Carcinoma, Lung Non-Small Cell Carcinoma, Melanoma, Non-Hodgkin Lymphoma
Register for Updates
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
NCT05878769
Recruiting
The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmonary disease (COPD) who have completed the 52-week placebo-controlled treatment period in parent studies GB43311 or GB44332.
Gender:
ALL
Ages:
Between 40 years and 90 years
Trial Updated:
08/01/2025
Locations: Paul A. Shapero, MD, PA, Bangor, Maine
Conditions: Chronic Obstructive Pulmonary Disease
Register for Updates
PRIMARY Ancillary Substudy
NCT07103733
Recruiting
The PRIMARY trial (NCT05051033), which compares mitral valve repair (MVr) to transcatheter-edge-to-edge-repair (TEER), offers a platform for conducting mechanistic studies to develop early insights into the pathophysiological processes by which mitral valve prolapse (MVP) can impact left ventricular (LV) myocardial structure and function, and, thereby, predispose to arrhythmias and sudden death. Such insights are key to identifying interventions to reduce the long-term sequelae of heart failure... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
08/01/2025
Locations: Maine Medical Center, Portland, Maine
Conditions: Mitral Valve Prolapse, Left Ventricular Fibrosis, Ventricular Arrhythmias
Register for Updates